Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer
Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Gly...
Gespeichert in:
| Veröffentlicht in: | International journal of oncology 2009-03, Vol.34 (3), p.649-656 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 656 |
|---|---|
| container_issue | 3 |
| container_start_page | 649 |
| container_title | International journal of oncology |
| container_volume | 34 |
| creator | SHIRAKAWA, Hirofumi KURONUMA, Toshimitsu KINOSHITA, Taira NAKATSURA, Tetsuya NISHIMURA, Yoshiko HASEBE, Takahiro NAKANO, Masayuki GOTOHDA, Naoto TAKAHASHI, Shinichiro NAKAGOHRI, Toshio KONISHI, Masaru KOBAYASHI, Nobuaki |
| description | Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Glypican-3 (GPC3) is serological and histochemical marker of hepatocellular carcinoma. In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs. GPC3 immunohistochemical staining was used to distinguish HCC from ICC by comparing with the conventional biomarker, alpha-fetoprotein (AFP). The immunostaining of GPC3 was identified in 78.3% (36/46) of HCCs, 60% (9/15) of well differentiated, 88.9% (16/18) of moderately differentiated and 84.6% (11/13) of poorly differentiated HCCs. It was negative in the ICCs. We confirmed that GPC3 expression is specific to HCC component (8/11, 72.7%) but few samples also showed weakly in ICC component (2/11, 18.2%) of CHC sections among 11 cases compared with HCC biomarkers including AFP and hepatocyto paraffin 1 (HepPar1), and ICC biomarkers cytokeratin (CK) 7 and CK19. Three cases in which the macroscopic features resembled ICC did not express GPC3 even in the pathological HCC component. Most (10/11, 91%) of the pathological cholangiocarcinoma components in CHC showed positive staining for CK7 and CK19. The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component of CHC. |
| doi_str_mv | 10.3892/ijo_00000190 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66916533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66916533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-c242b8337529d8088b14902027dd65ff99ca84198d666dcaa0a93c491c03f82b3</originalsourceid><addsrcrecordid>eNpNkL1PwzAUxD2AaClszMgLTAT8kbjxiBAUpEosMEcvjk1dHDvYCVL_exK1At5yw_10encIXVByy0vJ7uw2VGQ6KskRmtNRM5FzOUOnKW0JYUVB6AmaUckoE0LO0Xbldp1V4DOObcKAh6TN4HBj4cOH1FuFW4ifOmIT4mir0HbBa9_jYPBGd9AHpZ0bHESsICrrQwvYerwZWvDY2W89GV7peIaODbikzw-6QO9Pj28Pz9n6dfXycL_OVM54nymWs7rkfFkw2ZSkLGuaS8IIWzaNKIyRUkGZU1k2QohGARCQXOWSKsJNyWq-QNf73C6Gr0Gnvmptmp4Er8OQqrE3FQXnI3izB1UMKUVtqi7ase2uoqSa9qz-7znil4fcoW518wcfxhyBqwMASYEzcaxt0y_HKM0pKwj_AVL_f-k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66916533</pqid></control><display><type>article</type><title>Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SHIRAKAWA, Hirofumi ; KURONUMA, Toshimitsu ; KINOSHITA, Taira ; NAKATSURA, Tetsuya ; NISHIMURA, Yoshiko ; HASEBE, Takahiro ; NAKANO, Masayuki ; GOTOHDA, Naoto ; TAKAHASHI, Shinichiro ; NAKAGOHRI, Toshio ; KONISHI, Masaru ; KOBAYASHI, Nobuaki</creator><creatorcontrib>SHIRAKAWA, Hirofumi ; KURONUMA, Toshimitsu ; KINOSHITA, Taira ; NAKATSURA, Tetsuya ; NISHIMURA, Yoshiko ; HASEBE, Takahiro ; NAKANO, Masayuki ; GOTOHDA, Naoto ; TAKAHASHI, Shinichiro ; NAKAGOHRI, Toshio ; KONISHI, Masaru ; KOBAYASHI, Nobuaki</creatorcontrib><description>Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Glypican-3 (GPC3) is serological and histochemical marker of hepatocellular carcinoma. In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs. GPC3 immunohistochemical staining was used to distinguish HCC from ICC by comparing with the conventional biomarker, alpha-fetoprotein (AFP). The immunostaining of GPC3 was identified in 78.3% (36/46) of HCCs, 60% (9/15) of well differentiated, 88.9% (16/18) of moderately differentiated and 84.6% (11/13) of poorly differentiated HCCs. It was negative in the ICCs. We confirmed that GPC3 expression is specific to HCC component (8/11, 72.7%) but few samples also showed weakly in ICC component (2/11, 18.2%) of CHC sections among 11 cases compared with HCC biomarkers including AFP and hepatocyto paraffin 1 (HepPar1), and ICC biomarkers cytokeratin (CK) 7 and CK19. Three cases in which the macroscopic features resembled ICC did not express GPC3 even in the pathological HCC component. Most (10/11, 91%) of the pathological cholangiocarcinoma components in CHC showed positive staining for CK7 and CK19. The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component of CHC.</description><identifier>ISSN: 1019-6439</identifier><identifier>DOI: 10.3892/ijo_00000190</identifier><identifier>PMID: 19212669</identifier><language>eng</language><publisher>Athens: Editorial Academy of the International Journal of Oncology</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Bile Duct Neoplasms - metabolism ; Bile Duct Neoplasms - pathology ; Bile Ducts, Intrahepatic - metabolism ; Bile Ducts, Intrahepatic - pathology ; Biological and medical sciences ; Biomarkers, Tumor - biosynthesis ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - pathology ; Cholangiocarcinoma - metabolism ; Cholangiocarcinoma - pathology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Glypicans - biosynthesis ; Humans ; Immunohistochemistry ; Liver Neoplasms - metabolism ; Liver Neoplasms - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Tumors</subject><ispartof>International journal of oncology, 2009-03, Vol.34 (3), p.649-656</ispartof><rights>2009 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-c242b8337529d8088b14902027dd65ff99ca84198d666dcaa0a93c491c03f82b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21141250$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19212669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIRAKAWA, Hirofumi</creatorcontrib><creatorcontrib>KURONUMA, Toshimitsu</creatorcontrib><creatorcontrib>KINOSHITA, Taira</creatorcontrib><creatorcontrib>NAKATSURA, Tetsuya</creatorcontrib><creatorcontrib>NISHIMURA, Yoshiko</creatorcontrib><creatorcontrib>HASEBE, Takahiro</creatorcontrib><creatorcontrib>NAKANO, Masayuki</creatorcontrib><creatorcontrib>GOTOHDA, Naoto</creatorcontrib><creatorcontrib>TAKAHASHI, Shinichiro</creatorcontrib><creatorcontrib>NAKAGOHRI, Toshio</creatorcontrib><creatorcontrib>KONISHI, Masaru</creatorcontrib><creatorcontrib>KOBAYASHI, Nobuaki</creatorcontrib><title>Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer</title><title>International journal of oncology</title><addtitle>Int J Oncol</addtitle><description>Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Glypican-3 (GPC3) is serological and histochemical marker of hepatocellular carcinoma. In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs. GPC3 immunohistochemical staining was used to distinguish HCC from ICC by comparing with the conventional biomarker, alpha-fetoprotein (AFP). The immunostaining of GPC3 was identified in 78.3% (36/46) of HCCs, 60% (9/15) of well differentiated, 88.9% (16/18) of moderately differentiated and 84.6% (11/13) of poorly differentiated HCCs. It was negative in the ICCs. We confirmed that GPC3 expression is specific to HCC component (8/11, 72.7%) but few samples also showed weakly in ICC component (2/11, 18.2%) of CHC sections among 11 cases compared with HCC biomarkers including AFP and hepatocyto paraffin 1 (HepPar1), and ICC biomarkers cytokeratin (CK) 7 and CK19. Three cases in which the macroscopic features resembled ICC did not express GPC3 even in the pathological HCC component. Most (10/11, 91%) of the pathological cholangiocarcinoma components in CHC showed positive staining for CK7 and CK19. The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component of CHC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bile Duct Neoplasms - metabolism</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Bile Ducts, Intrahepatic - metabolism</subject><subject>Bile Ducts, Intrahepatic - pathology</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cholangiocarcinoma - metabolism</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Glypicans - biosynthesis</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Tumors</subject><issn>1019-6439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkL1PwzAUxD2AaClszMgLTAT8kbjxiBAUpEosMEcvjk1dHDvYCVL_exK1At5yw_10encIXVByy0vJ7uw2VGQ6KskRmtNRM5FzOUOnKW0JYUVB6AmaUckoE0LO0Xbldp1V4DOObcKAh6TN4HBj4cOH1FuFW4ifOmIT4mir0HbBa9_jYPBGd9AHpZ0bHESsICrrQwvYerwZWvDY2W89GV7peIaODbikzw-6QO9Pj28Pz9n6dfXycL_OVM54nymWs7rkfFkw2ZSkLGuaS8IIWzaNKIyRUkGZU1k2QohGARCQXOWSKsJNyWq-QNf73C6Gr0Gnvmptmp4Er8OQqrE3FQXnI3izB1UMKUVtqi7ase2uoqSa9qz-7znil4fcoW518wcfxhyBqwMASYEzcaxt0y_HKM0pKwj_AVL_f-k</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>SHIRAKAWA, Hirofumi</creator><creator>KURONUMA, Toshimitsu</creator><creator>KINOSHITA, Taira</creator><creator>NAKATSURA, Tetsuya</creator><creator>NISHIMURA, Yoshiko</creator><creator>HASEBE, Takahiro</creator><creator>NAKANO, Masayuki</creator><creator>GOTOHDA, Naoto</creator><creator>TAKAHASHI, Shinichiro</creator><creator>NAKAGOHRI, Toshio</creator><creator>KONISHI, Masaru</creator><creator>KOBAYASHI, Nobuaki</creator><general>Editorial Academy of the International Journal of Oncology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer</title><author>SHIRAKAWA, Hirofumi ; KURONUMA, Toshimitsu ; KINOSHITA, Taira ; NAKATSURA, Tetsuya ; NISHIMURA, Yoshiko ; HASEBE, Takahiro ; NAKANO, Masayuki ; GOTOHDA, Naoto ; TAKAHASHI, Shinichiro ; NAKAGOHRI, Toshio ; KONISHI, Masaru ; KOBAYASHI, Nobuaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-c242b8337529d8088b14902027dd65ff99ca84198d666dcaa0a93c491c03f82b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bile Duct Neoplasms - metabolism</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Bile Ducts, Intrahepatic - metabolism</topic><topic>Bile Ducts, Intrahepatic - pathology</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cholangiocarcinoma - metabolism</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Glypicans - biosynthesis</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>SHIRAKAWA, Hirofumi</creatorcontrib><creatorcontrib>KURONUMA, Toshimitsu</creatorcontrib><creatorcontrib>KINOSHITA, Taira</creatorcontrib><creatorcontrib>NAKATSURA, Tetsuya</creatorcontrib><creatorcontrib>NISHIMURA, Yoshiko</creatorcontrib><creatorcontrib>HASEBE, Takahiro</creatorcontrib><creatorcontrib>NAKANO, Masayuki</creatorcontrib><creatorcontrib>GOTOHDA, Naoto</creatorcontrib><creatorcontrib>TAKAHASHI, Shinichiro</creatorcontrib><creatorcontrib>NAKAGOHRI, Toshio</creatorcontrib><creatorcontrib>KONISHI, Masaru</creatorcontrib><creatorcontrib>KOBAYASHI, Nobuaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIRAKAWA, Hirofumi</au><au>KURONUMA, Toshimitsu</au><au>KINOSHITA, Taira</au><au>NAKATSURA, Tetsuya</au><au>NISHIMURA, Yoshiko</au><au>HASEBE, Takahiro</au><au>NAKANO, Masayuki</au><au>GOTOHDA, Naoto</au><au>TAKAHASHI, Shinichiro</au><au>NAKAGOHRI, Toshio</au><au>KONISHI, Masaru</au><au>KOBAYASHI, Nobuaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer</atitle><jtitle>International journal of oncology</jtitle><addtitle>Int J Oncol</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>34</volume><issue>3</issue><spage>649</spage><epage>656</epage><pages>649-656</pages><issn>1019-6439</issn><abstract>Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Glypican-3 (GPC3) is serological and histochemical marker of hepatocellular carcinoma. In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs. GPC3 immunohistochemical staining was used to distinguish HCC from ICC by comparing with the conventional biomarker, alpha-fetoprotein (AFP). The immunostaining of GPC3 was identified in 78.3% (36/46) of HCCs, 60% (9/15) of well differentiated, 88.9% (16/18) of moderately differentiated and 84.6% (11/13) of poorly differentiated HCCs. It was negative in the ICCs. We confirmed that GPC3 expression is specific to HCC component (8/11, 72.7%) but few samples also showed weakly in ICC component (2/11, 18.2%) of CHC sections among 11 cases compared with HCC biomarkers including AFP and hepatocyto paraffin 1 (HepPar1), and ICC biomarkers cytokeratin (CK) 7 and CK19. Three cases in which the macroscopic features resembled ICC did not express GPC3 even in the pathological HCC component. Most (10/11, 91%) of the pathological cholangiocarcinoma components in CHC showed positive staining for CK7 and CK19. The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component of CHC.</abstract><cop>Athens</cop><pub>Editorial Academy of the International Journal of Oncology</pub><pmid>19212669</pmid><doi>10.3892/ijo_00000190</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1019-6439 |
| ispartof | International journal of oncology, 2009-03, Vol.34 (3), p.649-656 |
| issn | 1019-6439 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66916533 |
| source | Spandidos Publications Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Bile Duct Neoplasms - metabolism Bile Duct Neoplasms - pathology Bile Ducts, Intrahepatic - metabolism Bile Ducts, Intrahepatic - pathology Biological and medical sciences Biomarkers, Tumor - biosynthesis Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cholangiocarcinoma - metabolism Cholangiocarcinoma - pathology Female Gastroenterology. Liver. Pancreas. Abdomen Glypicans - biosynthesis Humans Immunohistochemistry Liver Neoplasms - metabolism Liver Neoplasms - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Tumors |
| title | Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A23%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glypican-3%20is%20a%20useful%20diagnostic%20marker%20for%20a%20component%20of%20hepatocellular%20carcinoma%20in%20human%20liver%20cancer&rft.jtitle=International%20journal%20of%20oncology&rft.au=SHIRAKAWA,%20Hirofumi&rft.date=2009-03-01&rft.volume=34&rft.issue=3&rft.spage=649&rft.epage=656&rft.pages=649-656&rft.issn=1019-6439&rft_id=info:doi/10.3892/ijo_00000190&rft_dat=%3Cproquest_cross%3E66916533%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66916533&rft_id=info:pmid/19212669&rfr_iscdi=true |